[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fW--qOpqg3Zt8vEulva0MT-uIiLVmetIQQap4o29iGiE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",[4],65,false,0,24,21231,[12,15,18,20,23,26,28,31],{"name":13,"count":14},"Constipation",6,{"name":16,"count":17},"Bowel Dysfunction",5,{"name":19,"count":17},"Ileus",{"name":21,"count":22},"Opioid-Induced Constipation",4,{"name":24,"count":25},"Clostridium Difficile Infection",3,{"name":27,"count":25},"Renal Impairment",{"name":29,"count":30},"Complicated Urinary Tract Infection",2,{"name":32,"count":30},"Bloodloss",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,291,369,388,406,424,442,490,531,553,583,605,623,641,669,687,705,723,741,768,786,811,836,854,900,951,979,1015,1041,1059,1077,1095,1121,1139,1157,1184,1202,1220,1238,1256,1280,1298,1316,1334,1352,1370,1388,1416,1434,1459,1477,1504,1522,1552,1570,1588,1606,1624,1648,1674],{"intervention":43,"totalTrials":44,"cells":45},"daptomycin",22,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":104,"PHASE3":146,"PHASE4":197,"NA":289},{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[50,61,72,83,94],{"nctId":51,"briefTitle":52,"status":53,"phases":54,"primaryCompletion":55,"completion":55,"start":56,"enrollment":57,"conditions":58,"interventions":60},"NCT00490737","Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)","COMPLETED",[36],"2008-05-12","2007-08-12",12,[59],"End-Stage Renal Disease",[43],{"nctId":62,"briefTitle":63,"status":53,"phases":64,"primaryCompletion":65,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":71},"NCT00136292","Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics",[36],"2006-08-01","2006-08-09","2005-08-24",33,[70],"Gram-positive Bacterial Infections",[43],{"nctId":73,"briefTitle":74,"status":53,"phases":75,"primaryCompletion":76,"completion":76,"start":77,"enrollment":78,"conditions":79,"interventions":81},"NCT01019395","Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics",[36],"2012-03-20","2010-01-05",23,[80],"Gram Positive Bacterial Infection",[82],"Daptomycin",{"nctId":84,"briefTitle":85,"status":53,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":93},"NCT00882557","Study to Evaluate Daptomycin Given During Dialysis and After Dialysis",[36],"2009-07-17","2009-04-29",16,[91,92],"End-stage Renal Disease","Renal Failure Chronic Requiring Hemodialysis",[43,43],{"nctId":95,"briefTitle":96,"status":53,"phases":97,"primaryCompletion":98,"completion":98,"start":99,"enrollment":9,"conditions":100,"interventions":103},"NCT00679835","PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections",[36],"2008-11-20","2008-06-03",[101,102],"Gram Positive Infection","Concurrent Antibiotic Treatment",[43],{"trials":105,"activeCount":8},[106,120,131],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":118},"NCT00695903","Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia","TERMINATED",[37],"2010-08-24","2010-10-01","2008-09-17",38,[116,117],"Endocarditis, Bacterial","Infective Endocarditis",[43,119],"vancomycin",{"nctId":121,"briefTitle":122,"status":53,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT00426933","Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections",[37],"2007-09","2007-01",100,[128],"Soft Tissue Infections",[82,130],"Vancomycin",{"nctId":132,"briefTitle":133,"status":53,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT00428844","Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci",[37],"2010-03-26","2010-06-23","2007-06-26",75,[140],"Osteomyelitis",[43,43,119,142,143,144,145],"teicoplanin","nafcillin","oxacillin","flucloxacillin",{"trials":147,"activeCount":8},[148,157,165,176,188],{"nctId":149,"briefTitle":150,"status":53,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"conditions":154,"interventions":156},"NCT00538694","Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia",[38],"2001-09-30","2000-10-31",[155],"Pneumonia, Bacterial",[43],{"nctId":158,"briefTitle":159,"status":53,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"conditions":163,"interventions":164},"NCT00540072","Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae",[38],"2002-02-27","2001-07-30",[155],[43],{"nctId":166,"briefTitle":167,"status":53,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"conditions":172,"interventions":175},"NCT00093067","Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus",[38],"2004-11","2005-02","2002-03",[173,174],"Bacterial Endocarditis","Bacteremia",[43],{"nctId":177,"briefTitle":178,"status":53,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT01922011","Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)",[38],"2016-06-14","2016-12-20","2013-09-13",149,[185],"Acute Hematogenous Osteomyelitis",[82,130,187],"Nafcillin",{"nctId":189,"briefTitle":190,"status":109,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":138,"conditions":194,"interventions":196},"NCT00055198","Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria",[38],"2004-01-26","2002-12-19",[195],"Gram-Positive Bacterial Infections",[43],{"trials":198,"activeCount":8},[199,210,220,230,239,251,262,271,280],{"nctId":200,"briefTitle":201,"status":53,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT00711802","Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections",[39],"2013-10-11","2008-07-23",396,[207],"Skin Diseases, Infectious",[82,209],"Standard of Care",{"nctId":211,"briefTitle":212,"status":109,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT00651131","Cubicin(R) for Complicated Post-surgical Wound Infections",[39],"2005-03-01","2004-06-01",69,[218],"Wound Infections",[43],{"nctId":221,"briefTitle":222,"status":53,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":228},"NCT01728376","Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)",[39],"2016-01-20","2012-11-29",82,[174],[82,229],"Comparator",{"nctId":231,"briefTitle":232,"status":109,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":238},"NCT00102947","Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections",[39],"2006-11","2005-01",72,[128],[43],{"nctId":240,"briefTitle":241,"status":109,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},"NCT01104662","Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment",[39],"2012-06-12","2010-04-19",92,[247,248,27],"Complicated Skin and Skin Structure Infections","S. Aureus Bacteremia",[130,82,250],"Semi-Synthetic Penicillin",{"nctId":252,"briefTitle":253,"status":53,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT01419184","Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA",[39],"2012-09-01","2012-10-05","2011-09-09",250,[260],"Staphylococcal Skin Infections",[82,130],{"nctId":263,"briefTitle":264,"status":53,"phases":265,"primaryCompletion":66,"completion":66,"start":266,"enrollment":267,"conditions":268,"interventions":270},"NCT00295178","Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas",[39],"2006-02-20",80,[269],"Cellulitis",[82,130],{"nctId":272,"briefTitle":273,"status":109,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":9,"conditions":277,"interventions":278},"NCT00638157","Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)",[39],"2011-11-09","2009-02-13",[117],[43,279],"daptomycin and gentamicin",{"nctId":281,"briefTitle":282,"status":109,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":267,"conditions":286,"interventions":288},"NCT01175707","Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting",[39],"2011-11-17","2010-07-15",[287],"Complicated Skin or Skin Structure Infection",[82,130],{"trials":290,"activeCount":8},[],{"intervention":130,"totalTrials":292,"cells":293},11,{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":324,"PHASE4":349,"NA":367},{"trials":295,"activeCount":8},[],{"trials":297,"activeCount":8},[],{"trials":299,"activeCount":8},[300,312,316,320],{"nctId":301,"briefTitle":302,"status":53,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT01085591","Study of CB-183,315 in Participants With Clostridium Difficile Infection",[37],"2011-04-13","2011-05-13","2010-04-01",210,[24,309],"Diarrhea",[311,130],"CB-183,315",{"nctId":107,"briefTitle":108,"status":109,"phases":313,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":314,"interventions":315},[37],[116,117],[43,119],{"nctId":121,"briefTitle":122,"status":53,"phases":317,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":318,"interventions":319},[37],[128],[82,130],{"nctId":132,"briefTitle":133,"status":53,"phases":321,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":322,"interventions":323},[37],[140],[43,43,119,142,143,144,145],{"trials":325,"activeCount":8},[326,336,345],{"nctId":327,"briefTitle":328,"status":53,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT01597505","Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",[38],"2015-03-20","2012-05-16",606,[24],[335,130],"Surotomycin",{"nctId":337,"briefTitle":338,"status":53,"phases":339,"primaryCompletion":340,"completion":341,"start":331,"enrollment":342,"conditions":343,"interventions":344},"NCT01598311","A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",[38],"2015-07-26","2015-08-25",608,[24],[311,130],{"nctId":177,"briefTitle":178,"status":53,"phases":346,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":347,"interventions":348},[38],[185],[82,130,187],{"trials":350,"activeCount":8},[351,355,359,363],{"nctId":240,"briefTitle":241,"status":109,"phases":352,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":353,"interventions":354},[39],[247,248,27],[130,82,250],{"nctId":252,"briefTitle":253,"status":53,"phases":356,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":357,"interventions":358},[39],[260],[82,130],{"nctId":263,"briefTitle":264,"status":53,"phases":360,"primaryCompletion":66,"completion":66,"start":266,"enrollment":267,"conditions":361,"interventions":362},[39],[269],[82,130],{"nctId":281,"briefTitle":282,"status":109,"phases":364,"primaryCompletion":284,"completion":284,"start":285,"enrollment":267,"conditions":365,"interventions":366},[39],[287],[82,130],{"trials":368,"activeCount":8},[],{"intervention":209,"totalTrials":370,"cells":371},1,{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":386},{"trials":373,"activeCount":8},[],{"trials":375,"activeCount":8},[],{"trials":377,"activeCount":8},[],{"trials":379,"activeCount":8},[],{"trials":381,"activeCount":8},[382],{"nctId":200,"briefTitle":201,"status":53,"phases":383,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":384,"interventions":385},[39],[207],[82,209],{"trials":387,"activeCount":8},[],{"intervention":229,"totalTrials":370,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":404},{"trials":391,"activeCount":8},[],{"trials":393,"activeCount":8},[],{"trials":395,"activeCount":8},[],{"trials":397,"activeCount":8},[],{"trials":399,"activeCount":8},[400],{"nctId":221,"briefTitle":222,"status":53,"phases":401,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":402,"interventions":403},[39],[174],[82,229],{"trials":405,"activeCount":8},[],{"intervention":250,"totalTrials":370,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":422},{"trials":409,"activeCount":8},[],{"trials":411,"activeCount":8},[],{"trials":413,"activeCount":8},[],{"trials":415,"activeCount":8},[],{"trials":417,"activeCount":8},[418],{"nctId":240,"briefTitle":241,"status":109,"phases":419,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":420,"interventions":421},[39],[247,248,27],[130,82,250],{"trials":423,"activeCount":8},[],{"intervention":279,"totalTrials":370,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":440},{"trials":427,"activeCount":8},[],{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[],{"trials":433,"activeCount":8},[],{"trials":435,"activeCount":8},[436],{"nctId":272,"briefTitle":273,"status":109,"phases":437,"primaryCompletion":275,"completion":275,"start":276,"enrollment":9,"conditions":438,"interventions":439},[39],[117],[43,279],{"trials":441,"activeCount":8},[],{"intervention":443,"totalTrials":22,"cells":444},"CB-5945",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":486,"NA":488},{"trials":446,"activeCount":8},[],{"trials":448,"activeCount":8},[],{"trials":450,"activeCount":8},[],{"trials":452,"activeCount":8},[453,462,470,479],{"nctId":454,"briefTitle":455,"status":109,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT01901341","The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation",[38],"2014-02-13","2013-07-02",44,[21],[443],{"nctId":463,"briefTitle":464,"status":109,"phases":465,"primaryCompletion":457,"completion":457,"start":466,"enrollment":467,"conditions":468,"interventions":469},"NCT01901328","Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation",[38],"2013-04-07",49,[21],[443],{"nctId":471,"briefTitle":472,"status":109,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":478},"NCT01696643","Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation",[38],"2014-07-21","2012-10-12",1407,[21],[443],{"nctId":480,"briefTitle":464,"status":109,"phases":481,"primaryCompletion":457,"completion":457,"start":482,"enrollment":483,"conditions":484,"interventions":485},"NCT01901302",[38],"2013-05-20",61,[21],[443],{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[],{"intervention":491,"totalTrials":30,"cells":492},"Ceftolozane\u002FTazobactam",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":527,"NA":529},{"trials":494,"activeCount":8},[],{"trials":496,"activeCount":8},[],{"trials":498,"activeCount":8},[],{"trials":500,"activeCount":8},[501,512],{"nctId":502,"briefTitle":503,"status":109,"phases":504,"primaryCompletion":505,"completion":506,"start":507,"enrollment":22,"conditions":508,"interventions":510},"NCT01853982","Study of Intravenous Ceftolozane\u002FTazobactam Compared to Piperacillin\u002FTazobactam in Ventilator-Associated Pneumonia",[38],"2013-11-20","2013-12-08","2013-06-14",[509],"Ventilator-Associated Pneumonia (VAP)",[491,511],"Piperacillin\u002FTazobactam",{"nctId":513,"briefTitle":514,"status":53,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":524},"NCT02070757","Safety and Efficacy Study of Ceftolozane\u002FTazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)",[38],"2018-05-15","2018-06-06","2014-09-02",726,[521,522,523],"Healthcare-Associated Pneumonia","Ventilator-Associated Pneumonia","Lung Diseases",[525,526],"Ceftolozane\u002Ftazobactam","Meropenem",{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[],{"intervention":311,"totalTrials":30,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":549,"NA":551},{"trials":534,"activeCount":8},[],{"trials":536,"activeCount":8},[],{"trials":538,"activeCount":8},[539],{"nctId":301,"briefTitle":302,"status":53,"phases":540,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":541,"interventions":542},[37],[24,309],[311,130],{"trials":544,"activeCount":8},[545],{"nctId":337,"briefTitle":338,"status":53,"phases":546,"primaryCompletion":340,"completion":341,"start":331,"enrollment":342,"conditions":547,"interventions":548},[38],[24],[311,130],{"trials":550,"activeCount":8},[],{"trials":552,"activeCount":8},[],{"intervention":526,"totalTrials":30,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":579,"NA":581},{"trials":556,"activeCount":8},[],{"trials":558,"activeCount":8},[],{"trials":560,"activeCount":8},[],{"trials":562,"activeCount":8},[563,567],{"nctId":513,"briefTitle":514,"status":53,"phases":564,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":565,"interventions":566},[38],[521,522,523],[525,526],{"nctId":568,"briefTitle":569,"status":53,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT01445678","Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections",[38],"2013-10-03","2013-10-15","2011-12-23",494,[576],"Complicated Intra-abdominal Infection",[578,526],"CXA-201 and metronidazole",{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"intervention":143,"totalTrials":30,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":595,"PHASE4":601,"NA":603},{"trials":586,"activeCount":8},[],{"trials":588,"activeCount":8},[],{"trials":590,"activeCount":8},[591],{"nctId":132,"briefTitle":133,"status":53,"phases":592,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":593,"interventions":594},[37],[140],[43,43,119,142,143,144,145],{"trials":596,"activeCount":8},[597],{"nctId":177,"briefTitle":178,"status":53,"phases":598,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":599,"interventions":600},[38],[185],[82,130,187],{"trials":602,"activeCount":8},[],{"trials":604,"activeCount":8},[],{"intervention":511,"totalTrials":370,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":619,"NA":621},{"trials":608,"activeCount":8},[],{"trials":610,"activeCount":8},[],{"trials":612,"activeCount":8},[],{"trials":614,"activeCount":8},[615],{"nctId":502,"briefTitle":503,"status":109,"phases":616,"primaryCompletion":505,"completion":506,"start":507,"enrollment":22,"conditions":617,"interventions":618},[38],[509],[491,511],{"trials":620,"activeCount":8},[],{"trials":622,"activeCount":8},[],{"intervention":335,"totalTrials":370,"cells":624},{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":637,"NA":639},{"trials":626,"activeCount":8},[],{"trials":628,"activeCount":8},[],{"trials":630,"activeCount":8},[],{"trials":632,"activeCount":8},[633],{"nctId":327,"briefTitle":328,"status":53,"phases":634,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":635,"interventions":636},[38],[24],[335,130],{"trials":638,"activeCount":8},[],{"trials":640,"activeCount":8},[],{"intervention":642,"totalTrials":370,"cells":643},"Tedizolid Phophate",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":665,"NA":667},{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[],{"trials":649,"activeCount":8},[],{"trials":651,"activeCount":8},[652],{"nctId":653,"briefTitle":654,"status":53,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":661},"NCT02276482","Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)",[38],"2018-09-17","2015-03-25",120,[207,660],"Skin Diseases, Bacterial",[642,662,663,664],"Antibiotic comparator","Aztreonam","Metronidazole",{"trials":666,"activeCount":8},[],{"trials":668,"activeCount":8},[],{"intervention":662,"totalTrials":370,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":8},[],{"trials":674,"activeCount":8},[],{"trials":676,"activeCount":8},[],{"trials":678,"activeCount":8},[679],{"nctId":653,"briefTitle":654,"status":53,"phases":680,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":681,"interventions":682},[38],[207,660],[642,662,663,664],{"trials":684,"activeCount":8},[],{"trials":686,"activeCount":8},[],{"intervention":663,"totalTrials":370,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":8},[],{"trials":692,"activeCount":8},[],{"trials":694,"activeCount":8},[],{"trials":696,"activeCount":8},[697],{"nctId":653,"briefTitle":654,"status":53,"phases":698,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":699,"interventions":700},[38],[207,660],[642,662,663,664],{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[],{"intervention":664,"totalTrials":370,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":8},[],{"trials":710,"activeCount":8},[],{"trials":712,"activeCount":8},[],{"trials":714,"activeCount":8},[715],{"nctId":653,"briefTitle":654,"status":53,"phases":716,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":717,"interventions":718},[38],[207,660],[642,662,663,664],{"trials":720,"activeCount":8},[],{"trials":722,"activeCount":8},[],{"intervention":578,"totalTrials":370,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":737,"NA":739},{"trials":726,"activeCount":8},[],{"trials":728,"activeCount":8},[],{"trials":730,"activeCount":8},[],{"trials":732,"activeCount":8},[733],{"nctId":568,"briefTitle":569,"status":53,"phases":734,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":735,"interventions":736},[38],[576],[578,526],{"trials":738,"activeCount":8},[],{"trials":740,"activeCount":8},[],{"intervention":742,"totalTrials":370,"cells":743},"CXA-201",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":750,"PHASE4":764,"NA":766},{"trials":745,"activeCount":8},[],{"trials":747,"activeCount":8},[],{"trials":749,"activeCount":8},[],{"trials":751,"activeCount":8},[752],{"nctId":753,"briefTitle":754,"status":53,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":762},"NCT01345929","Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",[38],"2013-08-11","2013-09-04","2011-06-20",558,[29,761],"Pyelonephritis",[742,763],"Levofloxacin",{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"intervention":763,"totalTrials":370,"cells":769},{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":782,"NA":784},{"trials":771,"activeCount":8},[],{"trials":773,"activeCount":8},[],{"trials":775,"activeCount":8},[],{"trials":777,"activeCount":8},[778],{"nctId":753,"briefTitle":754,"status":53,"phases":779,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":780,"interventions":781},[38],[29,761],[742,763],{"trials":783,"activeCount":8},[],{"trials":785,"activeCount":8},[],{"intervention":787,"totalTrials":370,"cells":788},"Alviompan",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":807,"NA":809},{"trials":790,"activeCount":8},[],{"trials":792,"activeCount":8},[],{"trials":794,"activeCount":8},[],{"trials":796,"activeCount":8},[797],{"nctId":798,"briefTitle":799,"status":53,"phases":800,"primaryCompletion":801,"start":802,"enrollment":803,"conditions":804,"interventions":805},"NCT00259922","Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain",[38],"2006-06","2005-08",485,[16,13],[806,787],"Alvimopan",{"trials":808,"activeCount":8},[],{"trials":810,"activeCount":8},[],{"intervention":812,"totalTrials":370,"cells":813},"Tedizolid phosphate",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":832,"NA":834},{"trials":815,"activeCount":8},[],{"trials":817,"activeCount":8},[],{"trials":819,"activeCount":8},[],{"trials":821,"activeCount":8},[822],{"nctId":823,"briefTitle":824,"status":53,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":519,"conditions":828,"interventions":830},"NCT02019420","Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)",[38],"2018-06-22","2014-01-06",[829],"Pneumonia",[812,831],"Linezolid",{"trials":833,"activeCount":8},[],{"trials":835,"activeCount":8},[],{"intervention":831,"totalTrials":370,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":850,"NA":852},{"trials":839,"activeCount":8},[],{"trials":841,"activeCount":8},[],{"trials":843,"activeCount":8},[],{"trials":845,"activeCount":8},[846],{"nctId":823,"briefTitle":824,"status":53,"phases":847,"primaryCompletion":826,"completion":826,"start":827,"enrollment":519,"conditions":848,"interventions":849},[38],[829],[812,831],{"trials":851,"activeCount":8},[],{"trials":853,"activeCount":8},[],{"intervention":855,"totalTrials":25,"cells":856},"Ecallantide",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":858,"activeCount":8},[],{"trials":860,"activeCount":8},[],{"trials":862,"activeCount":8},[863,875,884],{"nctId":864,"briefTitle":865,"status":53,"phases":866,"primaryCompletion":867,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT00816023","A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume",[37],"2009-12","2010-01","2009-03",276,[32,872],"Surgical Procedures, Operative",[874],"ecallantide",{"nctId":876,"briefTitle":877,"status":53,"phases":878,"primaryCompletion":867,"completion":868,"start":879,"enrollment":880,"conditions":881,"interventions":882},"NCT00888940","Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery",[37],"2009-06",243,[32,872],[855,883],"Cyklokapron",{"nctId":885,"briefTitle":886,"status":109,"phases":887,"primaryCompletion":888,"completion":889,"start":890,"enrollment":138,"conditions":891,"interventions":893},"NCT00448864","Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair\u002FReplacement",[37],"2008-07-01","2008-08-01","2007-05-01",[892],"Blood Loss, Surgical",[855],{"trials":895,"activeCount":8},[],{"trials":897,"activeCount":8},[],{"trials":899,"activeCount":8},[],{"intervention":901,"totalTrials":25,"cells":902},"ADL5859",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":904,"activeCount":8},[],{"trials":906,"activeCount":8},[],{"trials":908,"activeCount":8},[909,922,933],{"nctId":910,"briefTitle":911,"status":53,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT00979953","Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee",[37],"2010-04","2010-06","2009-10",408,[918],"Osteoarthritis of the Knee",[901,920,921],"ADL5747","Oxycodone CR",{"nctId":923,"briefTitle":924,"status":53,"phases":925,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT00626275","Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis",[37],"2008-09","2007-10",46,[930],"Rheumatoid Arthritis",[901,932,901],"Naproxen",{"nctId":934,"briefTitle":935,"status":53,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":943},"NCT00603265","Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy",[37],"2008-08","2007-11",226,[941,942],"Peripheral Neuropathy","Neuropathic Pain",[901,944],"Duloxetine",{"trials":946,"activeCount":8},[],{"trials":948,"activeCount":8},[],{"trials":950,"activeCount":8},[],{"intervention":920,"totalTrials":30,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":954,"activeCount":8},[],{"trials":956,"activeCount":8},[],{"trials":958,"activeCount":8},[959,969],{"nctId":960,"briefTitle":961,"status":109,"phases":962,"primaryCompletion":963,"completion":963,"start":868,"enrollment":964,"conditions":965,"interventions":967},"NCT01058642","Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia",[37],"2010-12",41,[966],"Postherpetic Neuralgia",[920,968],"Pregabalin",{"nctId":910,"briefTitle":911,"status":53,"phases":970,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":971,"interventions":972},[37],[918],[901,920,921],{"trials":974,"activeCount":8},[],{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[],{"intervention":980,"totalTrials":30,"cells":981},"ADL5945 0.25 mg",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":983,"activeCount":8},[],{"trials":985,"activeCount":8},[],{"trials":987,"activeCount":8},[988,1000],{"nctId":989,"briefTitle":990,"status":53,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT01207427","Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain",[37],"2011-04-18","2011-06-28","2010-10-14",131,[997],"Opioid Induced Constipation",[999,980],"ADL5945 0.1 mg",{"nctId":1001,"briefTitle":1002,"status":53,"phases":1003,"primaryCompletion":1004,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1008},"NCT01275755","Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain",[37],"2011-07-15","2011-01-19",81,[13],[980],{"trials":1010,"activeCount":8},[],{"trials":1012,"activeCount":8},[],{"trials":1014,"activeCount":8},[],{"intervention":1016,"totalTrials":370,"cells":1017},"CXA-101",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1019,"activeCount":8},[],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[1024],{"nctId":1025,"briefTitle":1026,"status":53,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1033},"NCT00921024","Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections",[37],"2010-02-25","2010-03-11","2009-06-30",129,[29],[1016,1034],"Ceftazidime",{"trials":1036,"activeCount":8},[],{"trials":1038,"activeCount":8},[],{"trials":1040,"activeCount":8},[],{"intervention":1034,"totalTrials":370,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":8},[],{"trials":1046,"activeCount":8},[],{"trials":1048,"activeCount":8},[1049],{"nctId":1025,"briefTitle":1026,"status":53,"phases":1050,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1051,"interventions":1052},[37],[29],[1016,1034],{"trials":1054,"activeCount":8},[],{"trials":1056,"activeCount":8},[],{"trials":1058,"activeCount":8},[],{"intervention":968,"totalTrials":370,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":8},[],{"trials":1064,"activeCount":8},[],{"trials":1066,"activeCount":8},[1067],{"nctId":960,"briefTitle":961,"status":109,"phases":1068,"primaryCompletion":963,"completion":963,"start":868,"enrollment":964,"conditions":1069,"interventions":1070},[37],[966],[920,968],{"trials":1072,"activeCount":8},[],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[],{"intervention":999,"totalTrials":370,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":8},[],{"trials":1082,"activeCount":8},[],{"trials":1084,"activeCount":8},[1085],{"nctId":989,"briefTitle":990,"status":53,"phases":1086,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":1087,"interventions":1088},[37],[997],[999,980],{"trials":1090,"activeCount":8},[],{"trials":1092,"activeCount":8},[],{"trials":1094,"activeCount":8},[],{"intervention":1096,"totalTrials":370,"cells":1097},"CXA-101\u002F tazobactam and metronidazole",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1099,"activeCount":8},[],{"trials":1101,"activeCount":8},[],{"trials":1103,"activeCount":8},[1104],{"nctId":1105,"briefTitle":1106,"status":53,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1113},"NCT01147640","Safety and Efficacy Study to Compare IV CXA 101\u002FTazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections",[37],"2011-02-20","2011-03-25","2010-06-25",122,[576],[1096,1114],"meropenem plus saline placebo",{"trials":1116,"activeCount":8},[],{"trials":1118,"activeCount":8},[],{"trials":1120,"activeCount":8},[],{"intervention":1114,"totalTrials":370,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":8},[],{"trials":1126,"activeCount":8},[],{"trials":1128,"activeCount":8},[1129],{"nctId":1105,"briefTitle":1106,"status":53,"phases":1130,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1111,"conditions":1131,"interventions":1132},[37],[576],[1096,1114],{"trials":1134,"activeCount":8},[],{"trials":1136,"activeCount":8},[],{"trials":1138,"activeCount":8},[],{"intervention":883,"totalTrials":370,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":8},[],{"trials":1144,"activeCount":8},[],{"trials":1146,"activeCount":8},[1147],{"nctId":876,"briefTitle":877,"status":53,"phases":1148,"primaryCompletion":867,"completion":868,"start":879,"enrollment":880,"conditions":1149,"interventions":1150},[37],[32,872],[855,883],{"trials":1152,"activeCount":8},[],{"trials":1154,"activeCount":8},[],{"trials":1156,"activeCount":8},[],{"intervention":1158,"totalTrials":370,"cells":1159},"ADL5859 30 mg",{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1161,"activeCount":8},[],{"trials":1163,"activeCount":8},[],{"trials":1165,"activeCount":8},[1166],{"nctId":1167,"briefTitle":1168,"status":53,"phases":1169,"primaryCompletion":124,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1174},"NCT00993863","Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction",[37],"2007-06",201,[1173],"Acute Pain",[1158,1175,1176,1177],"ADL5859 100 mg","ADL5859 200 mg","ibuprofen 400 mg",{"trials":1179,"activeCount":8},[],{"trials":1181,"activeCount":8},[],{"trials":1183,"activeCount":8},[],{"intervention":1175,"totalTrials":370,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1187,"activeCount":8},[],{"trials":1189,"activeCount":8},[],{"trials":1191,"activeCount":8},[1192],{"nctId":1167,"briefTitle":1168,"status":53,"phases":1193,"primaryCompletion":124,"start":1170,"enrollment":1171,"conditions":1194,"interventions":1195},[37],[1173],[1158,1175,1176,1177],{"trials":1197,"activeCount":8},[],{"trials":1199,"activeCount":8},[],{"trials":1201,"activeCount":8},[],{"intervention":1176,"totalTrials":370,"cells":1203},{"EARLY_PHASE1":1204,"PHASE1":1206,"PHASE2":1208,"PHASE3":1214,"PHASE4":1216,"NA":1218},{"trials":1205,"activeCount":8},[],{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[1210],{"nctId":1167,"briefTitle":1168,"status":53,"phases":1211,"primaryCompletion":124,"start":1170,"enrollment":1171,"conditions":1212,"interventions":1213},[37],[1173],[1158,1175,1176,1177],{"trials":1215,"activeCount":8},[],{"trials":1217,"activeCount":8},[],{"trials":1219,"activeCount":8},[],{"intervention":1177,"totalTrials":370,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1223,"activeCount":8},[],{"trials":1225,"activeCount":8},[],{"trials":1227,"activeCount":8},[1228],{"nctId":1167,"briefTitle":1168,"status":53,"phases":1229,"primaryCompletion":124,"start":1170,"enrollment":1171,"conditions":1230,"interventions":1231},[37],[1173],[1158,1175,1176,1177],{"trials":1233,"activeCount":8},[],{"trials":1235,"activeCount":8},[],{"trials":1237,"activeCount":8},[],{"intervention":921,"totalTrials":370,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1250,"PHASE4":1252,"NA":1254},{"trials":1241,"activeCount":8},[],{"trials":1243,"activeCount":8},[],{"trials":1245,"activeCount":8},[1246],{"nctId":910,"briefTitle":911,"status":53,"phases":1247,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":1248,"interventions":1249},[37],[918],[901,920,921],{"trials":1251,"activeCount":8},[],{"trials":1253,"activeCount":8},[],{"trials":1255,"activeCount":8},[],{"intervention":1257,"totalTrials":370,"cells":1258},"HepeX-B",{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1260,"activeCount":8},[],{"trials":1262,"activeCount":8},[],{"trials":1264,"activeCount":8},[1265],{"nctId":1266,"briefTitle":1267,"status":109,"phases":1268,"completion":802,"conditions":1269,"interventions":1272},"NCT00228592","HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection",[37],[1270,1271],"Hepatitis B","Liver Transplantation",[1257,1273],"Hepatitis B Immune Globulin",{"trials":1275,"activeCount":8},[],{"trials":1277,"activeCount":8},[],{"trials":1279,"activeCount":8},[],{"intervention":1273,"totalTrials":370,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":8},[],{"trials":1285,"activeCount":8},[],{"trials":1287,"activeCount":8},[1288],{"nctId":1266,"briefTitle":1267,"status":109,"phases":1289,"completion":802,"conditions":1290,"interventions":1291},[37],[1270,1271],[1257,1273],{"trials":1293,"activeCount":8},[],{"trials":1295,"activeCount":8},[],{"trials":1297,"activeCount":8},[],{"intervention":142,"totalTrials":370,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":8},[],{"trials":1303,"activeCount":8},[],{"trials":1305,"activeCount":8},[1306],{"nctId":132,"briefTitle":133,"status":53,"phases":1307,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":1308,"interventions":1309},[37],[140],[43,43,119,142,143,144,145],{"trials":1311,"activeCount":8},[],{"trials":1313,"activeCount":8},[],{"trials":1315,"activeCount":8},[],{"intervention":144,"totalTrials":370,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":8},[],{"trials":1321,"activeCount":8},[],{"trials":1323,"activeCount":8},[1324],{"nctId":132,"briefTitle":133,"status":53,"phases":1325,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":1326,"interventions":1327},[37],[140],[43,43,119,142,143,144,145],{"trials":1329,"activeCount":8},[],{"trials":1331,"activeCount":8},[],{"trials":1333,"activeCount":8},[],{"intervention":145,"totalTrials":370,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":8},[],{"trials":1339,"activeCount":8},[],{"trials":1341,"activeCount":8},[1342],{"nctId":132,"briefTitle":133,"status":53,"phases":1343,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":1344,"interventions":1345},[37],[140],[43,43,119,142,143,144,145],{"trials":1347,"activeCount":8},[],{"trials":1349,"activeCount":8},[],{"trials":1351,"activeCount":8},[],{"intervention":932,"totalTrials":370,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":8},[],{"trials":1357,"activeCount":8},[],{"trials":1359,"activeCount":8},[1360],{"nctId":923,"briefTitle":924,"status":53,"phases":1361,"primaryCompletion":926,"completion":926,"start":927,"enrollment":928,"conditions":1362,"interventions":1363},[37],[930],[901,932,901],{"trials":1365,"activeCount":8},[],{"trials":1367,"activeCount":8},[],{"trials":1369,"activeCount":8},[],{"intervention":944,"totalTrials":370,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":8},[],{"trials":1375,"activeCount":8},[],{"trials":1377,"activeCount":8},[1378],{"nctId":934,"briefTitle":935,"status":53,"phases":1379,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":1380,"interventions":1381},[37],[941,942],[901,944],{"trials":1383,"activeCount":8},[],{"trials":1385,"activeCount":8},[],{"trials":1387,"activeCount":8},[],{"intervention":1389,"totalTrials":370,"cells":1390},"Alvimopan 0.5 mg\u002Fday",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1392,"activeCount":8},[],{"trials":1394,"activeCount":8},[],{"trials":1396,"activeCount":8},[1397],{"nctId":1398,"briefTitle":1399,"status":109,"phases":1400,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":1404,"conditions":1405,"interventions":1407},"NCT00331045","Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid",[37],"2006-10","2006-12","2006-04",21,[1406,13],"Cancer",[1408,1389,1409],"alvimopan","Alvimopan 1 mg\u002Fday",{"trials":1411,"activeCount":8},[],{"trials":1413,"activeCount":8},[],{"trials":1415,"activeCount":8},[],{"intervention":1409,"totalTrials":370,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1419,"activeCount":8},[],{"trials":1421,"activeCount":8},[],{"trials":1423,"activeCount":8},[1424],{"nctId":1398,"briefTitle":1399,"status":109,"phases":1425,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":1404,"conditions":1426,"interventions":1427},[37],[1406,13],[1408,1389,1409],{"trials":1429,"activeCount":8},[],{"trials":1431,"activeCount":8},[],{"trials":1433,"activeCount":8},[],{"intervention":1435,"totalTrials":370,"cells":1436},"CXA-101\u002Ftazobactam",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1451,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1438,"activeCount":8},[],{"trials":1440,"activeCount":8},[1441],{"nctId":1442,"briefTitle":1443,"status":53,"phases":1444,"primaryCompletion":1445,"completion":1445,"start":914,"enrollment":1446,"conditions":1447,"interventions":1449},"NCT02508753","Safety Study Designed to Study the Effects of Two Different Doses of CXA-101\u002FTazobactam, a Low Dose and a High Dose, on the QT\u002FQTc Intervals in Healthy Subjects",[36],"2010-07",52,[1448],"Healthy",[1435,1435,1450],"Moxifloxacin",{"trials":1452,"activeCount":8},[],{"trials":1454,"activeCount":8},[],{"trials":1456,"activeCount":8},[],{"trials":1458,"activeCount":8},[],{"intervention":1450,"totalTrials":370,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1469,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1462,"activeCount":8},[],{"trials":1464,"activeCount":8},[1465],{"nctId":1442,"briefTitle":1443,"status":53,"phases":1466,"primaryCompletion":1445,"completion":1445,"start":914,"enrollment":1446,"conditions":1467,"interventions":1468},[36],[1448],[1435,1435,1450],{"trials":1470,"activeCount":8},[],{"trials":1472,"activeCount":8},[],{"trials":1474,"activeCount":8},[],{"trials":1476,"activeCount":8},[],{"intervention":1478,"totalTrials":370,"cells":1479},"Ceftolozane\u002FTazobactam - Multiple Doses",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1481,"activeCount":8},[],{"trials":1483,"activeCount":8},[1484],{"nctId":1485,"briefTitle":1486,"status":53,"phases":1487,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1494},"NCT02387372","Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane\u002FTazobactam in Participants With Pneumonia (MK-7625A-007)",[36],"2017-06-15","2017-06-16","2015-02-05",37,[1493,829],"Critically Ill",[1478,1495],"Ceftolozane\u002FTazobactam - Single Dose",{"trials":1497,"activeCount":8},[],{"trials":1499,"activeCount":8},[],{"trials":1501,"activeCount":8},[],{"trials":1503,"activeCount":8},[],{"intervention":1495,"totalTrials":370,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1507,"activeCount":8},[],{"trials":1509,"activeCount":8},[1510],{"nctId":1485,"briefTitle":1486,"status":53,"phases":1511,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1512,"interventions":1513},[36],[1493,829],[1478,1495],{"trials":1515,"activeCount":8},[],{"trials":1517,"activeCount":8},[],{"trials":1519,"activeCount":8},[],{"trials":1521,"activeCount":8},[],{"intervention":1523,"totalTrials":370,"cells":1524},"Ceftolozane\u002FTazobactam 1000\u002F500 mg",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1526,"activeCount":8},[],{"trials":1528,"activeCount":8},[1529],{"nctId":1530,"briefTitle":1531,"status":53,"phases":1532,"primaryCompletion":1533,"completion":1488,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1539},"NCT02266706","Pharmacokinetic and Safety Study of Ceftolozane\u002FTazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)",[36],"2017-06-08","2014-09-17",43,[1537,1538],"Proven or Suspected Gram-negative Bacterial Infection","Peri-operative Prophylaxis",[1523,1540,1541,1542,1543],"Ceftolozane\u002FTazobactam 30\u002F15 mg\u002Fkg","Ceftolozane\u002FTazobactam 20\u002F10 mg\u002Fkg","Ceftolozane\u002FTazobactam 18\u002F9 mg\u002Fkg","Ceftolozane\u002FTazobactam 12\u002F6 mg\u002Fkg",{"trials":1545,"activeCount":8},[],{"trials":1547,"activeCount":8},[],{"trials":1549,"activeCount":8},[],{"trials":1551,"activeCount":8},[],{"intervention":1540,"totalTrials":370,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1555,"activeCount":8},[],{"trials":1557,"activeCount":8},[1558],{"nctId":1530,"briefTitle":1531,"status":53,"phases":1559,"primaryCompletion":1533,"completion":1488,"start":1534,"enrollment":1535,"conditions":1560,"interventions":1561},[36],[1537,1538],[1523,1540,1541,1542,1543],{"trials":1563,"activeCount":8},[],{"trials":1565,"activeCount":8},[],{"trials":1567,"activeCount":8},[],{"trials":1569,"activeCount":8},[],{"intervention":1541,"totalTrials":370,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":8},[],{"trials":1575,"activeCount":8},[1576],{"nctId":1530,"briefTitle":1531,"status":53,"phases":1577,"primaryCompletion":1533,"completion":1488,"start":1534,"enrollment":1535,"conditions":1578,"interventions":1579},[36],[1537,1538],[1523,1540,1541,1542,1543],{"trials":1581,"activeCount":8},[],{"trials":1583,"activeCount":8},[],{"trials":1585,"activeCount":8},[],{"trials":1587,"activeCount":8},[],{"intervention":1542,"totalTrials":370,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1598,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[1594],{"nctId":1530,"briefTitle":1531,"status":53,"phases":1595,"primaryCompletion":1533,"completion":1488,"start":1534,"enrollment":1535,"conditions":1596,"interventions":1597},[36],[1537,1538],[1523,1540,1541,1542,1543],{"trials":1599,"activeCount":8},[],{"trials":1601,"activeCount":8},[],{"trials":1603,"activeCount":8},[],{"trials":1605,"activeCount":8},[],{"intervention":1543,"totalTrials":370,"cells":1607},{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[1612],{"nctId":1530,"briefTitle":1531,"status":53,"phases":1613,"primaryCompletion":1533,"completion":1488,"start":1534,"enrollment":1535,"conditions":1614,"interventions":1615},[36],[1537,1538],[1523,1540,1541,1542,1543],{"trials":1617,"activeCount":8},[],{"trials":1619,"activeCount":8},[],{"trials":1621,"activeCount":8},[],{"trials":1623,"activeCount":8},[],{"intervention":1625,"totalTrials":370,"cells":1626},"bevenopran",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1640,"PHASE3":1642,"PHASE4":1644,"NA":1646},{"trials":1628,"activeCount":8},[],{"trials":1630,"activeCount":8},[1631],{"nctId":1632,"briefTitle":1633,"status":109,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1639},"NCT02508740","Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment",[36],"2013-12","2013-09",31,[27],[1625],{"trials":1641,"activeCount":8},[],{"trials":1643,"activeCount":8},[],{"trials":1645,"activeCount":8},[],{"trials":1647,"activeCount":8},[],{"intervention":1649,"totalTrials":370,"cells":1650},"MK-6183",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[1655],{"nctId":1656,"briefTitle":1657,"status":53,"phases":1658,"primaryCompletion":1659,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1665},"NCT02341599","Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)",[36],"2015-04-13","2015-04-20","2014-12-11",40,[1664,27],"Healthy Volunteers",[1649],{"trials":1667,"activeCount":8},[],{"trials":1669,"activeCount":8},[],{"trials":1671,"activeCount":8},[],{"trials":1673,"activeCount":8},[],{"intervention":806,"totalTrials":57,"cells":1675},{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1704,"PHASE4":1761,"NA":1772},{"trials":1677,"activeCount":8},[],{"trials":1679,"activeCount":8},[],{"trials":1681,"activeCount":8},[1682,1691,1700],{"nctId":1683,"briefTitle":1684,"status":53,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1690},"NCT00135577","Study 767905\u002F008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects",[37],"2007-04","2004-09",67,[1406,16],[1408],{"nctId":1692,"briefTitle":1693,"status":53,"phases":1694,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1699},"NCT00101998","Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication",[37],"2006-05-01","2003-10-01",233,[13,16],[1408],{"nctId":1398,"briefTitle":1399,"status":109,"phases":1701,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":1404,"conditions":1702,"interventions":1703},[37],[1406,13],[1408,1389,1409],{"trials":1705,"activeCount":8},[1706,1715,1724,1732,1741,1749,1753],{"nctId":1707,"briefTitle":1708,"status":53,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":1712,"conditions":1713,"interventions":1714},"NCT00388479","Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction\u002F Postoperative Ileus",[38],"2003-11","2001-12",666,[19],[806],{"nctId":1716,"briefTitle":1717,"status":53,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT00241722","Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain",[38],"2007-02-01","2005-08-01",805,[16,13],[806],{"nctId":1725,"briefTitle":1726,"status":53,"phases":1727,"completion":1728,"start":802,"enrollment":1729,"conditions":1730,"interventions":1731},"NCT00256932","Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain",[38],"2006-05",518,[16,13],[1408],{"nctId":1733,"briefTitle":1734,"status":53,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1740},"NCT00388258","Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction\u002FPostoperative Ileus",[38],"2002-12-01","2001-03-01",451,[19],[806],{"nctId":1742,"briefTitle":1734,"status":53,"phases":1743,"primaryCompletion":1744,"completion":1744,"start":1745,"enrollment":1746,"conditions":1747,"interventions":1748},"NCT00388401",[38],"2003-06","2002-01",510,[19],[806],{"nctId":798,"briefTitle":799,"status":53,"phases":1750,"primaryCompletion":801,"start":802,"enrollment":803,"conditions":1751,"interventions":1752},[38],[16,13],[806,787],{"nctId":1754,"briefTitle":1734,"status":53,"phases":1755,"primaryCompletion":1756,"completion":1756,"start":1757,"enrollment":1758,"conditions":1759,"interventions":1760},"NCT00205842",[38],"2005-12","2004-06",660,[19],[1408],{"trials":1762,"activeCount":8},[1763],{"nctId":1764,"briefTitle":1765,"status":53,"phases":1766,"primaryCompletion":1767,"completion":1767,"start":869,"enrollment":1768,"conditions":1769,"interventions":1771},"NCT00708201","A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy",[39],"2012-01",280,[1770],"Postoperative Ileus",[806],{"trials":1773,"activeCount":8},[1774],{"nctId":1775,"briefTitle":1776,"status":53,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":913,"enrollment":1779,"conditions":1780,"interventions":1781},"NCT01150760","Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database",[],"2010-08",7050,[19],[806]]